David Amsellem

Piper Sandler | Healthcare

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #2155 out of 4537 analysts, they have issued 37 stock ratings with a success rate of 76.35% and an average return of 14.92%.

David Amsellem has a well-established track record, with 37 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 76.35% and an average return of 14.92%, underscoring their expertise and ability to identify winning opportunities for investors.

#2155

Out of 4537

37

Total Ratings

+76.35%

Success Rate

+14.92%

Average Return

Recent Ratings Analysis

BIIB

Feb 09, 2026

Target

$177.00

Current

$188.99

Performance

-2.49%

David Amsellem rated BIIB as Neutral on Feb 09, 2026, setting a price target of 177. The Hold stance appears justified, as shares hovered around 188.99 with a -2.49% move.

VTRS

Jan 28, 2026

Target

$12.00

Current

$15.95

Performance

22.98%

On Jan 28, 2026, VTRS was given a Neutral rating by David Amsellem, with a target price of 12. The stock rallied from 15.95 to 15.95 after the Hold rating, surprising to the upside.

BMY

Jan 28, 2026

Target

$66.00

Current

$60.86

Performance

11.42%

BMY received a Overweight rating from David Amsellem on Jan 28, 2026, aiming for 66. Momentum has favored the Buy call, with shares climbing from 60.86 to 60.86, rewarding those who trusted the recommendation.

AXSM

Jan 16, 2026

Target

$223.00

Current

$184.30

Performance

3.97%

On Jan 16, 2026, David Amsellem published a Overweight outlook on AXSM, with a target of 223. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 184.3.

FENC

Jan 09, 2026

Target

$18.00

Current

$7.79

Performance

0.26%

David Amsellem on Jan 09, 2026 assigned FENC a Overweight rating, with a price target of 18. The recommendation remains pending validation as shares consolidate around 7.79.

TEVA

Dec 22, 2025

Target

$40.00

Current

$34.37

Performance

10.12%

On Dec 22, 2025, David Amsellem reaffirmed TEVA with a Overweight rating, targeting 40. The recommendation was supported by strong follow-through as the stock rose from 34.37 to 34.37.

JAZZ

Dec 10, 2025

Target

$219.00

Current

$165.63

Performance

0.40%

JAZZ was rated Overweight by David Amsellem on Dec 10, 2025, with a price objective of 219. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

ESPR

Nov 25, 2025

Target

$9.00

Current

$3.39

Performance

-8.13%

On Nov 25, 2025, David Amsellem initiated coverage on ESPR with a Overweight rating and target of 9. The Buy call has yet to be validated as shares remain 5.61 away from the target.

AMGN

Nov 14, 2025

Target

$381.00

Current

$364.65

Performance

8.29%

David Amsellem issued a Overweight recommendation for AMGN on Nov 14, 2025, price target set at 381. Investors following the Buy call captured upside momentum, with shares now at 364.65.

AQST

Nov 07, 2025

Target

$8.00

Current

$3.86

Performance

-36.09%

On Nov 07, 2025, AQST was evaluated by David Amsellem, who gave a Overweight rating and target of 8. Investors saw limited payoff as shares fell short of the 8 target.

XERS

Nov 07, 2025

Target

$8.00

Current

$7.22

Performance

-2.83%

David Amsellem rated XERS as Neutral on Nov 07, 2025, setting a price target of 8. The Hold stance appears justified, as shares hovered around 7.22 with a -2.83% move.

ABBV

Nov 05, 2025

Target

$289.00

Current

$222.44

Performance

2.62%

On Nov 05, 2025, ABBV was given a Overweight rating by David Amsellem, with a target price of 289. The stock traded sideways with a 2.62% move, keeping the bullish thesis unresolved.

INDV

Oct 31, 2025

Target

$41.00

Current

$33.46

Performance

13.93%

INDV received a Overweight rating from David Amsellem on Oct 31, 2025, aiming for 41. Momentum has favored the Buy call, with shares climbing from 33.46 to 33.46, rewarding those who trusted the recommendation.

AMRX

Oct 31, 2025

Target

$13.00

Current

$14.76

Performance

36.41%

On Oct 31, 2025, David Amsellem published a Overweight outlook on AMRX, with a target of 13. Shares gained 36.41%, underscoring the accuracy of the bullish outlook toward 13.

NBIX

Oct 29, 2025

Target

$179.00

Current

$137.65

Performance

-0.27%

David Amsellem on Oct 29, 2025 assigned NBIX a Overweight rating, with a price target of 179. The recommendation remains pending validation as shares consolidate around 137.65.

ALKS

Oct 23, 2025

Target

$45.00

Current

$34.72

Performance

15.58%

On Oct 23, 2025, David Amsellem reaffirmed ALKS with a Overweight rating, targeting 45. The recommendation was supported by strong follow-through as the stock rose from 34.72 to 34.72.

SUPN

Oct 09, 2025

Target

$65.00

Current

$51.18

Performance

3.37%

SUPN was rated Overweight by David Amsellem on Oct 09, 2025, with a price objective of 65. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

AMPH

Aug 08, 2025

Target

$25.00

Current

$28.57

Performance

19.99%

On Aug 08, 2025, David Amsellem initiated coverage on AMPH with a Neutral rating and target of 25. The Hold stance underestimated the stock’s strength as it gained 19.99%.

CORT

Aug 01, 2025

Target

$121.00

Current

$40.97

Performance

-40.62%

David Amsellem issued a Overweight recommendation for CORT on Aug 01, 2025, price target set at 121. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

SAGE

Jun 17, 2025

Target

$8.50

Current

$8.68

Performance

-4.82%

On Jun 17, 2025, SAGE was evaluated by David Amsellem, who gave a Neutral rating and target of 8.5. Hold sentiment was validated by subdued trading with no breakout beyond 8.68.

OPTN

Mar 21, 2025

Target

$9.00

Current

$9.60

Performance

4.92%

David Amsellem rated OPTN as Neutral on Mar 21, 2025, setting a price target of 9. The Hold stance appears justified, as shares hovered around 9.6 with a 4.92% move.

COLL

Feb 04, 2025

Target

$36.00

Current

$46.75

Performance

51.15%

On Feb 04, 2025, COLL was given a Neutral rating by David Amsellem, with a target price of 36. The stock rallied from 46.75 to 46.75 after the Hold rating, surprising to the upside.

ITCI

Jan 14, 2025

Target

$132.00

Current

$131.87

Performance

3.92%

ITCI received a Neutral rating from David Amsellem on Jan 14, 2025, aiming for 132. Shares remained flat at 131.87, aligning with the neutral rating.

AVDL

Jan 10, 2025

Target

$13.00

Current

$21.63

Performance

173.80%

On Jan 10, 2025, David Amsellem published a Overweight outlook on AVDL, with a target of 13. Shares gained 173.80%, underscoring the accuracy of the bullish outlook toward 13.

ANIP

Oct 11, 2024

Target

$68.00

Current

$79.91

Performance

39.85%

David Amsellem on Oct 11, 2024 assigned ANIP a Overweight rating, with a price target of 68. The Buy call aligned well with market performance, producing a gain of 39.85%.

BHC

Aug 02, 2024

Target

$3.00

Current

$6.16

Performance

9.41%

On Aug 02, 2024, David Amsellem reaffirmed BHC with a Underweight rating, targeting 3. The Sell recommendation anticipated weakness, as shares dropped 9.41%.

PCRX

Jul 03, 2024

Target

$42.00

Current

$21.24

Performance

-1.94%

PCRX was rated Overweight by David Amsellem on Jul 03, 2024, with a price objective of 42. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

RVNC

May 10, 2024

Target

$11.00

Current

$3.65

Performance

9.94%

On May 10, 2024, David Amsellem initiated coverage on RVNC with a Overweight rating and target of 11. The stock’s climb of 9.94% since the call highlights the foresight in the rating.

OGN

Apr 29, 2024

Target

$24.00

Current

$7.81

Performance

-58.68%

David Amsellem issued a Overweight recommendation for OGN on Apr 29, 2024, price target set at 24. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Frequency Asked Questions

Who is David Amsellem?

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector.

What is David Amsellem's success rate?

David Amsellem currently has a success rate of +76.35%.

How many ratings has David Amsellem issued?

David Amsellem has issued 37 stock ratings so far.

What is the average return of David Amsellem's calls?

Their stock ratings have generated an average return of +14.92%.

What is David Amsellem's ranking?

David Amsellem is ranked #2155 out of 4537 analysts.

What types of ratings does David Amsellem give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Amsellem?

You can follow David Amsellem by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Amsellem?

Their latest rating was a Hold on BIIB issued on 2026-02-09.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep